Thermal characterization and kinetic study of the antiretroviral tenofovir disoproxil fumarate

Silva, Jéssica; Figueirêdo, Camila; Medeiros Vieira, Amanda; Roca Soares, Mônica; Albuquerque, Miracy; Soares-Sobrinho, José; Lyra, Magaly; Rolim, Larissa; Rolim-Neto, Pedro
December 2017
Journal of Thermal Analysis & Calorimetry;Dec2017, Vol. 130 Issue 3, p1643
Academic Journal
Tenofovir disoproxil fumarate (TDF) is an antiretroviral belonging to the class of nucleotide analog reverse transcriptase inhibitors, approved for the use against HIV/Aids and hepatitis B. The objective of this study was to evaluate the thermal compatibility and non-isothermal kinetic degradation of TDF with pharmaceutical adjuvants used in its tablet dosage form. TDF in binary mixtures with these excipients (BM) was prepared at 1:1 (mass%). Starting with thermoanalytical techniques (differential scanning calorimetry and thermogravimetric analysis/DTG) were select some BM with signs of interaction and complementary techniques of X-ray diffraction (XRD), infrared spectroscopy (IR) and kinetic degradation were used to elucidate the drug-excipient interactions. The purity of TDF was 98.28%, with the fusion peak at 117.53 °C followed by the main degradation event at 146.49 °C. The BM with lactose and magnesium stearate (MgS) were selected as promoted interaction with the drug based on the anticipation of the fusion peak of TDF, with a probable occurrence of a Maillard reaction between TDF and lactose. According to FTIR, these interactions were confirmed by an intermolecular hydrogen binding; however, the XRD analyses only indicate some loss of drug crystallinity in the BM profiles after the heating process. Kinetic degradation showed a kinetic reaction of first order, a variation of activation energy negligible for the BM TDF + MgS (5%) and a greater variation in its value for the formulation (15%) in relation to the isolated TDF, thus indicating a higher negative interference of the whole excipients to guarantee the thermal stability of TDF. This study provided detailed information on the interaction between TDF and the excipients composing the dosage form as a first study of thermal compatibility involving this drug that aims to guide in the delineation of other formulations containing this drug.


Related Articles

  • A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection. Likanonsakul, Sirirat; Suntisuklappon, Bussakorn; Nitiyanontakij, Ravee; Prasithsirikul, Wisit; Nakayama, Emi E.; Shioda, Tatsuo; Sangsajja, Chariya // PLoS ONE;1/25/2016, Vol. 11 Issue 1, p1 

    Background: In Thailand, the combined generic anti-retroviral drug stavudine/lamivudine/nevirapine (d4T/3TC/NVP) has been used to treat human immunodeficiency virus (HIV)-infected individuals since 2001. Due to relatively frequent adverse effects, d4T gradually has been replaced with tenofovir...

  • Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Wyen, Christoph; Hendra, Heidy; Siccardi, Marco; Platten, Martin; Jaeger, Hans; Harrer, Thomas; Esser, Stefan; Bogner, Johannes R.; Brockmeyer, Norbert H.; Bieniek, Bernhard; Rockstroh, Juergen; Hoffmann, Christian; Stoehr, Albrecht; Michalik, Claudia; Dlugay, Verena; Jetter, Alexander; Knechten, Heribert; Klinker, Hartwig; Skaletz-Rorowski, Adriane; Fätkenheuer, Gerd // Journal of Antimicrobial Chemotherapy (JAC);Sep2011, Vol. 66 Issue 9, p2092 

    Objectives Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR)...

  • Tenofovir disoproxil fumarate.  // Reactions Weekly;Apr2015, Vol. 1547 Issue 1, p253 

    The article presents a case study of two patients who developed tenofovir disoproxile fumarate nephrotoxicity after receiving anti-retroviral therapy for HIV AIDS.

  • Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. Taylor, Stephen; Jayasuriya, Ashini; Fisher, Martin; Allan, Sris; Wilkins, Ed; Gilleran, Gerry; Heald, Lisa; Fidler, Sarah; Owen, Andrew; Back, David; Smit, Erasmus // Journal of Antimicrobial Chemotherapy (JAC);Mar2012, Vol. 67 Issue 3, p675 

    Objectives We designed two different studies to evaluate two different combination antiretroviral therapy (cART) stopping strategies namely a ‘staggered stop’ approach (STOP 1 study) and a ‘protected stop’ approach (STOP 2 study) to find the best ‘universal...

  • Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. Todesco, Eve; Rodriguez, Christophe; Morand-Joubert, Laurence; Mercier-Darty, Mélanie; Desire, Nathalie; Wirden, Marc; Girard, Pierre-Marie; Katlama, Christine; Calvez, Vincent; Marcelin, Anne-Geneviève // Journal of Antimicrobial Chemotherapy (JAC);May2015, Vol. 70 Issue 5, p1503 

    Objectives: Resistant minority variants present before ART can be a source of virological failure. This has been shown for NRTIs, NNRTIs and CCR5 inhibitors. However, very few data are available for the detection of such minority resistant variants that could be selected at virological failure...

  • Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand.  // AIDS Research & Therapy;2012, Vol. 9, p6 

    The article offers information on a study conducted by the authors related to hepatitis b virus (HBV) in HIV/HBV coinfected patients in Thailand. It states that the patients were given antiretroviral tenofovir after which early hepatic flare (EHF) was observed in 22 percent patients. It mentions...

  • of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention. Mujugira, Andrew; Baeten, Jared M.; Donnell, Deborah; Ndase, Patrick; Mugo, Nelly R.; Barnes, Linda; Campbell, James D.; Wangisi, Jonathan; Tappero, Jordan W.; Bukusi, Elizabeth; Cohen, Craig R.; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Were, Edwin; Fife, Kenneth H.; Kiarie, James; Farquhar, Carey; John-Stewart, Grace; Kidoguchi, Lara // PLoS Clinical Trials;Oct2011, Vol. 8 Issue 10, Special section p1 

    Introduction: Stable heterosexual HIV-1 serodiscordant couples in Africa have high HIV-1 transmission rates and are a critical population for evaluation of new HIV-1 prevention strategies. The Partners PrEP Study is a randomized, double-blind, placebo-controlled trial of tenofovir and...

  • Antiretroviral Medication and HIV Prevention: New Steps Forward and New Questions. Mayer, Kenneth H.; Krakower, Douglas // Annals of Internal Medicine;2/21/2012, Vol. 156 Issue 4, p312 

    During the past 2 years, several pivotal clinical trials have proven that the use of antiretrovirals by HIV-infected and at-risk uninfected persons can decrease the probability of HIV being transmitted sexually. The initial chemoprophylaxis studies evaluated tenofovir administered topically or...

  • Antworten zu �HIV-Infektion und antiretrovirale Therapie� aus PRAXIS Nr. 1.  // Praxis (16618157);1/16/2013, Vol. 102 Issue 2, p118 

    No abstract available.

  • Neuropsychiatric effects of tenofovir in comparison with other antiretroviral drugs. Ferrer1,2, Kathleen; Rakhmanina1,2, Natella // Neurobehavioral HIV Medicine;2013, Vol. 5, p1 

    Tenofovir is a widely used antiretroviral medication indicated to treat adults and children infected with HIV. Current guidelines for the management of HIV infection recommend tenofovir disoproxil fumarate (TDF) as a component of the preferred first-line combination antiretroviral therapy. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics